Literature DB >> 10546834

Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing.

P Sinha1, G Hütter, E Köttgen, M Dietel, D Schadendorf, H Lage.   

Abstract

In search of novel mechanisms that may lead to the development of chemoresistance of malignant tumors of the large bowel we used two-dimensional electrophoresis to identify proteins that were overexpressed in colorectal and fibrosarcoma cell lines that were resistant towards mitoxantrone. This cytostatic drug is known to lead to atypical multidrug resistance, i.e., the classical mechanism of multidrug resistance (MDR) accompanied by the overexpression of P-glycoprotein (P-gp) is ineffective. Using mass spectrometry and microsequencing we found adenine phosphoribosyl transferase and breast cancer specific gene 1 (BCSG1) overexpressed in the resistant colorectal tumor cell line. In the chemoresistant fibrosarcoma cell line we found two proteins that were overexpressed. One was identified as Rho-guanine dinucleotide phosphate (Rho-GDP) dissociation inhibitor and the other had sequence homologies with yeast protein yer-7. The putative role of these proteins is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10546834     DOI: 10.1002/(SICI)1522-2683(19991001)20:14<2961::AID-ELPS2961>3.0.CO;2-L

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  8 in total

Review 1.  Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?

Authors:  Francisco S Chung; Jayson S Santiago; Miguel Francisco M De Jesus; Camille V Trinidad; Melvin Floyd E See
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

2.  Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma.

Authors:  Masaaki Ito; Takaki Hiwasa; Satoshi Yajima; Takashi Suzuki; Yoko Oshima; Tatsuki Nanami; Makoto Sumazaki; Fumiaki Shiratori; Shu-Yang Li; Yasuo Iwadate; Kazuo Sugimoto; Masahiro Mori; Satoshi Kuwabara; Hirotaka Takizawa; Hideaki Shimada
Journal:  Esophagus       Date:  2022-07-03       Impact factor: 3.671

3.  RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells.

Authors:  Zhong Zheng; Xiang-Yi He; Jian-Fang Li; Bei-Qin Yu; Xue-Hua Chen; Jun Ji; Jia-Nian Zhang; Qin-Long Gu; Zheng-Gang Zhu; Bing-Ya Liu
Journal:  Oncol Lett       Date:  2012-10-01       Impact factor: 2.967

Review 4.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

5.  Current awareness.

Authors:  R Drysdale; L Bayraktaroglu
Journal:  Yeast       Date:  2000-06-30       Impact factor: 3.239

6.  Current awareness on comparative and functional genomics.

Authors: 
Journal:  Yeast       Date:  2000-09-30       Impact factor: 3.239

7.  RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells.

Authors:  Zhong Zheng; Bingya Liu; Xiaohua Wu
Journal:  Cancer Cell Int       Date:  2015-04-15       Impact factor: 5.722

8.  14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.

Authors:  In-Kyu Kim; Sun-Mi Park; Hee Jun Cho; Kyoung Eun Baek; In-Koo Nam; Seung-Ho Park; Ki-Jun Ryu; Jinhyun Ryu; Jungil Choi; Soon-Chan Hong; Jae Won Kim; Chang Won Lee; Sang Soo Kang; Jiyun Yoo
Journal:  Oncotarget       Date:  2013-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.